Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.

[1]  B. Dréno,et al.  Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database , 2021, ESMO open.

[2]  A. Hauschild,et al.  Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[3]  R. Dummer,et al.  Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study , 2019, The British journal of dermatology.

[4]  M. Beylot-Barry,et al.  [Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma]. , 2019 .

[5]  J. Grob,et al.  Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Zalaudek,et al.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. , 2019, European journal of cancer.

[7]  C. Barker,et al.  Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. , 2019, Journal of the American Academy of Dermatology.

[8]  T. Jouary,et al.  [Creation, implementation and objectives of CARADERM, a national network for rare skin carcinomas - Adnexal neoplasm part]. , 2019, Annales de dermatologie et de venereologie.

[9]  Philip R. Cohen,et al.  Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Carlino,et al.  Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma , 2018, Journal of immunotherapy.

[11]  Philip R. Cohen,et al.  Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies , 2017, Oncoimmunology.

[12]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. , 2017, European journal of cancer.

[13]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[14]  A. Chang,et al.  Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities , 2017, JAMA dermatology.

[15]  J. Taube,et al.  Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade , 2017, Journal of Immunotherapy for Cancer.

[16]  R. Schneiderbauer,et al.  Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer , 2017, The British journal of dermatology.

[17]  I. Lowy,et al.  Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 , 2016, Journal of Immunotherapy for Cancer.

[18]  G. Goldenberg,et al.  Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study. , 2016, Journal of the American Academy of Dermatology.

[19]  Philip R. Cohen,et al.  Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy , 2016, npj Genomic Medicine.

[20]  J. Strasswimmer,et al.  Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. , 2016, JAMA dermatology.

[21]  J. Blay,et al.  Equal access to innovative therapies and precision cancer care , 2016, Nature Reviews Clinical Oncology.

[22]  K. Sarin,et al.  An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib , 2015, Clinical Cancer Research.

[23]  J. Grob,et al.  Defining and recognising locally advanced basal cell carcinoma , 2015, European Journal of Dermatology.

[24]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[25]  R. Dummer,et al.  Basal cell carcinomas in a tertiary referral centre: a systematic analysis , 2014, The British journal of dermatology.

[26]  A. Hauschild,et al.  Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. , 2014, European journal of cancer.